Topic: gastrointestinal tumors
Rapt Therapeutics is giving Hanmi the rights to its lead program in South Korea and greater China for $10 million upfront and millions in milestones.
The data sparked a triple-digit surge in Deciphera’s stock price, even though details of the results leave scope to question ripretinib’s prospects.
Aslan has been hit by the news that its lead drug varlitinib missed the mark in a gastric cancer trial, sending its shares down almost 16%.
Despite the focus on immuno-oncology right now, Deciphera has data showing there is still plenty to talk about when it comes to kinase inhibitors.
New York biotech Rgenix has raised $40 million to advance drugs for solid tumors and gastrointestinal cancers.
AbbVie has terminated an early-stage trial of an antibody-drug conjugate for solid tumors.
Bristol-Myers Squibb has dropped its option to buy single-asset cancer biotech F-star Alpha.
Lexicon Pharmaceuticals saw its shares bounce 8% premarket this morning on news out late last night that the FDA had approved its oral med Xermelo (telotristat ethyl) for patients with certain GI tumors suffering from the rare condition known as carcinoid syndrome diarrhea.